CD274 and breast carcinoma: Since it has been shown that PARP inhibitors upregulate PD-L1 expression in breast cancer cell lines [46], the combination of PARP inhibitors with anti-PD-L1 therapy could significantly increase therapeutic efficacy in those IBC patients with HRR mutations.